Astrana Health, Inc. (ASTH): Results of Operations and Financial Condition
Astrana Health, Inc. (ASTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622348d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Astrana Health, Inc. Reports Second Quarter 2026 Results Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET · Reports revenue of $972.5 million, up 49% year-over-year, net income of
How this was made
The 30-second read
Why it matters
The key tradable items are the reported Q2 financials and the updated 2026 adjusted EBITDA guidance, which can shift valuation multiples and expectations for cash generation.
Market read
Strong Q2 growth and profitability metrics, plus updated guidance ranges for Q3 and full-year 2026, create a clear catalyst for repricing ASTH expectations.
What to watch
Traders may focus on the sustainability of free cash flow and the drivers behind the Care Partners revenue growth, not just top-line and adjusted EBITDA.
Background
This is an SEC 8-K with Exhibit 99.1 covering Astrana’s Q2 2026 results, operating highlights, and updated guidance, plus a same-day earnings call.
Ticker impact
Astrana reported Q2 2026 revenue of $972.5M (+49% YoY) and raised 2026 adjusted EBITDA guidance, alongside updated Q3 revenue and EBITDA ranges.
Likely positive bias for the stock into the next trading session as traders reprice 2026 EBITDA and cash flow expectations.
The filing discloses multiple hard datapoints (revenue, net income, adjusted EBITDA, free cash flow) and provides explicit updated guidance ranges for Q3 and full-year 2026.
Market effects
Reinforces demand for physician-centric, technology-enabled value-based care platforms, potentially supporting sentiment toward similar healthcare services models.
Limited direct regional spillover; primarily company-specific.
Low global relevance beyond US healthcare services investors.
Counterpoint
Guidance is still a range and the company notes no assurance results won’t differ materially; growth could normalize after reinvestment.
Key entities
- companyAstrana Health, Inc.
NASDAQ-listed physician-centric, technology-enabled healthcare company reporting Q2 2026 results and updated guidance.
- executiveBrandon Sim
President and CEO quoted on performance and guidance confidence.
